Application value of rosuvastatin in metabolic syndrome
Liu Weiwei
Yu Xiao
Li Bo
Abstract：Objective To evaluate the application value of rosuvastatin in metabolic syndrome (MS).Methods Ninety-two MS patients from November 2010 to May 2012 were randomly divided into two groups according to distribution principle of minimum unbalance index:rosuvastatin group (46 cases) receiving rosuvastatin 10 mg/d and atorvastatin group (46 cases) receiving atorvastatin 10 mg/d.The treatment lasted for 12 weeks.The primary and secondary outcome indexes 12 weeks after treatment were compared between groups.The primary outcome indexes included ratios of apolipoprotein B/apolipoprotein A1 (ApoB/ApoA1) and triglyceride/high-density lipoprotein cholesterol (TG/HDL-C),levels of high-sensitivity C-reactive protein (hs-CRP),tumor necrosis factor-α (TNF-α),interleukin-6 (IL-6),IL-18;the secondary outcome indexes included ApoB,ApoA1,total cholesterol (TC),low-density lipoprotein cholesterol (LDL-C),TG,HDL-C,fasting plasma glucose (FPG),2 h postprandial blood glucose (2 h PG),fasting insulin (FIN),insulin resistance index (HOMA-IR),systolic blood pressure (SBP),diastolic blood pressure (DBP),uric acid (UA),urine albumin excretionrate (UAER) and body mass index (BMI).The adverse reactions were observed.Results Twelve patients were lost to follow-up during treatment,40 patients from each group completed the research.After 12-week of treatment,the serum levels of ApoB/ApoA1,TG/HDL-C,hs-CRP,TNF-α,IL-6,IL-18,ApoB,TC,LDL-C,TG,FIN,HOMA-IR,SBP,DBP,UA,UAER were significantly decreased compared those before treatment in rosuvastatin group[(0.63 ±0.22) vs (1.26 ±0.25),(1.6 ±0.5) vs (2.7 ±0.6),(2.4 ±0.4) mg/L vs (6.9 ± 1.4) mg/L,(13 ±4) ng/L vs (28 ±7) ng/L,(13 ±4) ng/L vs (26 ±7) ng/L,(173 ±51) ng/L vs (318 ±90) ng/L,(0.83 ±0.23) g/L vs (1.58 ±0.29) g/L,(3.5 ±0.7) mmol/L vs (5.8 ±0.9) mmol/L,(2.0 ±0.5) mmol/L vs(3.5±0.5) mmol/L,(1.9±0.6) mmol/L vs (2.9±0.6) mrnol/L,(6.9±1.9) mU/L vs(12.1 ±2.9) mU/L,(1.6±0.3) vs (3.4±0.6),(135±13) mmHg vs (145 ±13) mmHg,(85 ±8) mmHg vs (94±9) mmHg,(295 ±42) μmol/L vs (385 ±54) μmol/L,(22.5 ±2.6) μg/min vs (29.9 ±3.4) μg/min] and in atorvastatin group [(0.92±0.24) vs (1.24±0.23),(1.8 ±0.5) vs (2.7 ±0.7),(3.5 ±0.7) mg/L vs (6.8 ±1.4) mg/L,(19±6) ng/L vs (27±7) ng/L,(19±6) ng/L vs (26±7) ng/L,(246±75) ng/L vs (311 ±92) ng/L,(1.14 ±0.26) g/L vs (1.56 ±0.27) g/L,(4.7 ±0.6) mmol/L vs (5.6 ±0.8) mmol/L,(2.6 ±0.6) mmol/L vs (3.5 ±0.5) mmol/L,(2.0 ±0.5) mmol/L vs (2.9 ±0.7) mmol/L,(8.9 ±2.3) mU/L vs(12.0±2.9) mU/L,(2.2±0.3) vs (3.4±0.5),(136±12) mmHg vs (144±14) mmHg,(86±9) mmHg vs(93 ± 9) mmHg,(327 ± 48) μmol/L vs (380 ± 51) μmol/L,(23.0 ± 2.8) μg/min vs (29.8 ± 3.3) μg/min](P ＜ 0.01).The serum levels of ApoA1,HDL-C,FPG,2 h PG and BMI were not significantly different between groups (P ＞0.05).The levels of ApoB/ApoA1,TG/HDL-C,hs-CRP,TNF-α,IL-6,IL-18,ApoB,TC,LDL-C,FIN,HOMA-IR,UA in rosuvastatin group were significantly lower than those in atorvastatin group (P ＜0.05) and the other indicators were not significantly different between groups 12 weeks after treatment (P ＞0.05).The safety indicators in rosuvastatin group were not significantly changed after treatment (P ＞ 0.05).No serious adverse reactions occurred in both groups.Conclusion Rosuvastatin can significantly reduce the ratios of ApoB/ApoA1 and TG/HDL-C ratio,the levels of inflammatory factors and UA,improve insulin resistance in patients with MS,and its security is also fine.
Keywords：Metabolic syndromeRosuvastatinApolipoprotein BApolipoprotein A1TriglycerideHigh-density lipoprotein cholesterolInflammation
Publication Date：2016-08-30
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：6( 1173-1178 )